Metabolic Syndrome

Document waist circumference, fasting triglycerides, HDL cholesterol, blood pressure, and fasting glucose at the same assessment. Revised NCEP metabolic syndrome requires at least 3 of 5 findings: waist circumference at least 102 cm in men or at least 88 cm in women; triglycerides at least 150 mg/dL; HDL cholesterol below 40 mg/dL in men or below 50 mg/dL in women; blood pressure at least 130/85 mm Hg; or fasting glucose at least 100 mg/dL. Treatment for any of these abnormalities counts toward the revised definition. jaccjaccThe Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis

Use the diagnosis as a trigger for integrated cardiovascular, kidney, metabolic, and obesity assessment rather than as an endpoint. Metabolic syndrome is associated with increased risk of type 2 diabetes and cardiovascular disease; its principal component abnormalities track with abdominal adiposity and insulin resistance. Nature+2NatureEffect of therapeutic lifestyle change on metabolic ...AHA JournalsPrevention Conference VII | CirculationScienceDirectMetabolic syndrome: risk factors, diagnosis, pathogenesis, ...

At the index visit, determine whether the patient has established clinical cardiovascular disease, type 2 diabetes, CKD, obesity, or metabolic dysfunction-associated steatotic liver disease risk. In primary care, practical integrated assessment includes blood pressure, lipid profile, diabetes screening, obesity assessment, kidney function and albuminuria, and noninvasive liver fibrosis testing when liver-metabolic risk is being evaluated. ScienceDirectScienceDirectAssessment and management of cardiovascular–kidney–liver metabolic-syndrome in the primary care setting: A multidisciplinary consensus statement

Patients with metabolic syndrome and moderate- to high-risk CKD, metabolic risk factors, or both but without subclinical or clinical cardiovascular disease fit CKM stage 2. In this stage, management should shift from recognition to timely treatment of metabolic risk factors and CKD to prevent progression to clinical cardiovascular disease and kidney failure. jaccjacc2026 AHA/ACC/ADA/ASN Guideline for the Prevention ...

Calculate 10-year cardiovascular risk with the PREVENT-CVD equation when making primary-prevention medication decisions. A 10-year PREVENT-CVD risk of at least 7.5% is used to guide pharmacotherapy discussions in CKM prevention and is also the guideline threshold cited for intensive blood-pressure lowering in stage 1 hypertension. jacc+1jacc2026 AHA/ACC/ADA/ASN Guideline for the Prevention ...jaccUse of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology

For patients with type 2 diabetes and CKM stage 2 or 3 whose 10-year PREVENT-CVD risk is at least 7.5%, discuss initiation or intensification of GLP-1-based therapy, an SGLT2 inhibitor, or combination therapy for cardioprotection. Choice should account for the patient’s kidney disease, obesity-treatment goals, glycemic status, treatment burden, and preferences. jaccjaccUse of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology

Reassess metabolic risk factors at least yearly in CKM stage 2. Use serial measurements to identify worsening glucose, blood pressure, triglycerides, kidney risk, or obesity early enough to intensify lifestyle, obesity, cardioprotective diabetes, kidney-protective, antihypertensive, or lipid-lowering therapy. jaccjacc2026 AHA/ACC/ADA/ASN Guideline for the Prevention ...

Use structured lifestyle treatment as the foundation for every phenotype. Lifestyle-associated weight loss averages approximately 5% and is associated with lower blood pressure, triglycerides, fasting glucose, and incident type 2 diabetes. Weight loss improves the cardinal features of metabolic syndrome, making it a high-yield intervention when several components coexist. jacc+1jacc2025 Concise Clinical Guidance: An ACC Expert ...AHA JournalsGuidelines for the Prevention of Stroke in Patients ...

Escalate beyond lifestyle intervention when obesity and its metabolic consequences remain clinically important. Contemporary obesity pharmacotherapy can produce approximately 10% to 20% weight loss and is associated with reductions in metabolic dysfunction-associated steatotic liver disease, type 2 diabetes, obstructive sleep apnea, and cardiovascular events. jaccjacc2025 Concise Clinical Guidance: An ACC Expert ...

Consider bariatric surgery as a higher-intensity option for appropriately selected patients when the anticipated benefit justifies procedural risk and follow-up demands. Bariatric surgery can achieve approximately 25% weight loss and has demonstrated reductions in all-cause mortality and cardiovascular consequences of obesity. jaccjacc2025 Concise Clinical Guidance: An ACC Expert ...

For patients with type 2 diabetes and elevated PREVENT-CVD risk, incorporate cardioprotective GLP-1-based therapy and/or SGLT2 inhibition into the weight and metabolic plan rather than treating glycemia in isolation. The cited CKM guidance uses a 7.5% or higher 10-year PREVENT-CVD risk threshold in CKM stage 2 or 3 to frame this discussion. jaccjaccUse of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology

Separate the diagnostic blood-pressure component from the treatment threshold. In metabolic syndrome without diabetes, antihypertensive drugs are prescribed at blood pressure of at least 140/90 mm Hg in the cited hypertension guidance; 130 to 139/85 to 89 mm Hg is managed with lifestyle modification to prevent progression. With diabetes, start antihypertensive therapy at 130/80 mm Hg or higher, with a target below 130/80 mm Hg. NatureNatureChapter 7. Hypertension complicated by other diseases | Hypertension Research

When pharmacotherapy is needed in hypertension with obesity or metabolic syndrome, ACE inhibitors or ARBs are recommended in the cited guidance because of metabolic considerations. Weight control through dietary and exercise therapy has blood-pressure-lowering effects and should continue alongside medication. NatureNatureChapter 7. Hypertension complicated by other diseases | Hypertension Research

For dysglycemia or type 2 diabetes, prioritize agents with cardiovascular and kidney benefit when those risks are present. Current CKM guidance emphasizes cardioprotective antihyperglycemic agents in type 2 diabetes and kidney-protective agents in CKD to reduce adverse cardiovascular and kidney events. jaccjacc2026 AHA/ACC/ADA/ASN Guideline for the Prevention ...

Manage hypertriglyceridemia and the broader lipid profile according to current lipid guidance after PREVENT-CVD risk estimation. CKM stage 2 management includes treatment of hypertriglyceridemia and hypertension, while dyslipidemia guidance incorporates quantitative risk assessment to guide initiation and intensification of lipid-lowering therapy. jacc+1jacc2026 AHA/ACC/ADA/ASN Guideline for the Prevention ...jaccUse of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology

Do not use low HDL cholesterol as an isolated treatment target in this framework. Its clinical value is as a diagnostic risk component that should prompt attention to the accompanying adiposity, triglyceride, glucose, blood-pressure, and global cardiovascular-risk pattern. jaccjaccThe Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis

At least annually in CKM stage 2, repeat the metabolic risk-factor assessment and use the trajectory—not merely a single threshold crossing—to intensify intervention. Rising blood pressure, fasting glucose, triglycerides, waist circumference, albuminuria, or declining kidney function should prompt reassessment of lifestyle treatment, obesity therapy, cardioprotective diabetes therapy, kidney-protective therapy, and preventive cardiovascular medications. jacc+1jacc2026 AHA/ACC/ADA/ASN Guideline for the Prevention ...ScienceDirectAssessment and management of cardiovascular–kidney–liver metabolic-syndrome in the primary care setting: A multidisciplinary consensus statement

Escalate the evaluation when metabolic syndrome coexists with established cardiovascular disease, moderate- to high-risk CKD, diabetes, or suspected liver fibrosis. These conditions change the expected benefit from therapies with cardiovascular, kidney, and weight-related effects and require integrated rather than siloed management. jacc+2jacc2026 AHA/ACC/ADA/ASN Guideline for the Prevention ...jaccUse of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of CardiologyScienceDirectAssessment and management of cardiovascular–kidney–liver metabolic-syndrome in the primary care setting: A multidisciplinary consensus statement

Use shared decision-making when PREVENT-CVD risk is at least 7.5%, particularly in patients with type 2 diabetes and CKM stage 2 or 3. The decision should explicitly weigh cardioprotective GLP-1-based therapy, SGLT2 inhibition, or both against treatment complexity and the patient’s weight, glycemic, kidney, and cardiovascular priorities. jaccjaccUse of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology